HI Owl V Fox,
Given this paragraph from paper on Actinogen website, do you see where they could work together?“Notwithstanding these limitations, results of this study indicate that increased plasma cortisol levels in combination with Aβ1 are associated with accelerated decline in global cognition, episodic memory, and executive function in preclinical AD. These findings suggest that the combination of cortisol and Aβ assessments may be useful biomarkers in predicting cognitive decline in preclinical AD.”
Also, do you think ACW will also be chasing a similar approval route? Ie, prove drug is safe to take, talk FDA into approving, then do the large Ph4 trial?
Cheers
Under valued stock, page-74
-
- There are more pages in this discussion • 103 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
-0.001(4.00%) |
Mkt cap ! $70.68M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.4¢ | $133.5K | 5.461M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 4693575 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 8756804 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| ACW (ASX) Chart |